Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Maze Therapeutics announced its Q2 2026 financial results alongside clinical updates on its Phase 2 programs targeting APOL1-mediated kidney disease and phenylketonuria. Enrollment in multiple Phase 2 trials is progressing on schedule, with important data expected in late 2026 and 2027. The company holds a strong cash position of nearly $495 millio…